Lithuanians worry about fallout from Belarus sanctions
INTERVIEW: “The weekend’s protests were the Russian people's, not the opposition’s” – Maxim Reznik
Western Balkans citizens legally resident in EU equal to 14% of region’s population
International Ice Hockey Federation (IIHF) has stripped Belarus of the right to hold the World Championship this year
Russia's Sberbank makes a move in e-commerce with Goods.ru deal
Putin strikes a conciliatory tone in his World Economic Forum speech but warns of an “all against all” fight if tensions are ignored
OUTLOOK 2021 Russia
@russian_market sacked by UBS for supporting Navalny
Public support is collapsing for The People’s Servant Party
Ukraine’s industrial output jumped 4.8% y/y in December
State-owned Ukrgasbank signs off on convertible €30mn IFC loan ahead of its privatisation
National Bank of Ukraine retains a key policy rate at 6%, the outlook of the CPI deteriorates
Estonia's two big parties agree on grand coalition
VISEGRAD BLOG: Central Europe's populists need a new strategy for Biden
LONG READ: The oligarch problem
China to be excluded from Czech tender for new Dukovany nuclear unit
Czech billionaire Kellner´s PPF makes another bid for Moneta Money Bank
Czech MPs pass protectionist food law in violation of EU rules
M&A in Central and Eastern Europe fell 16% in value in 2020, says CMS report
Hungarian government plans to regulate big tech to stop 'ban' on rightwing views
Hungarian vehicle makers hit by supply chain shortage
Protests sweep Poland after government launches near-total abortion ban
Polish parcel locker operator InPost soars in Euronext Amsterdam debut
Polish industrial production continues boom in December
OUTLOOK 2021 Slovakia
BRICKS & MORTAR: Rosier future beckons for CEE retailers after year of change and disruption
FDI inflows to CEE down 58% in 1H20 but rebound expected
BALKAN BLOG: Only better waste management can clean rivers of trash
Pandemic pushes public debt close to 80% of GDP in Albania and Montenegro
BALKAN BLOG: Superstition and resentment surround vaccination plans
Albania needs reforms for e-commerce to thrive, says World Bank
Bosnia's exports in 2020 amounted to BAM10.5bn, trade deficit to BAM6.3bn
Bulgaria’s latest nuclear u-turn
Retailers and restaurant owners threaten protests in Bulgaria if reopening is delayed
Bulgaria's Biodit first company to IPO on new BEAM market
Spring lockdown caused spike in online transactions in Croatia
ING: Growth in the Balkans: from zero to hero again?
Labour demand down 28% y/y in Croatia in 2020
Kosovo’s biggest opposition party risks being unable to run in general election
OUTLOOK 2021 Moldova
Storming parliaments: New Europe's greatest hits
World Bank revises projection for Moldova’s 2020 GDP decline to 7.2%
Montenegro’s special prosecution probes finance minister over €750mn Eurobond issue
North Macedonia’s state-owned loss-makers await new owners
North Macedonia plans to cut personal income tax in IT sector to zero in 2023
Romanian cybersecurity company Safetech floats shares amid rising investor interest
Romania government to pursue “ambitious” timetable for justice reforms
Private finance mobilised by development banks up 9% to $175bn in 2019
EBRD and WBIF support fast broadband in rural Serbia
Slovenia plans region's longest-tenor Eurobond
Slovenian crypto payment system enters Thai market
Slovenia’s economic sentiment indicator up 2.2 pp m/m in January
Slovenia lost €10bn by neglecting wood industry for decades
Turkish groceries delivery app Getir goes online in London
D’S Damat franchise deals ‘show Turkey’s hard-pressed mall operators becoming their own tenants’
Turkey’s benchmark rate held as concerns over faltering recovery come to fore
Following war with Armenia, Azerbaijan gains control of lucrative gold mines
CAUCASUS BLOG : What can Biden offer the Caucasus and Stans, all but forgotten about by Trump?
Armenia ‘to extend life of its 1970s Metsamor nuclear power plant after 2026’
OUTLOOK 2021 Azerbaijan
OUTLOOK 2021 Georgia
“Try me” not telecoms minister Iran’s president tells hardliners in internet row
Iran’s President Khamenei menaces private citizen Trump
Iran’s technology minister indicted for failing to properly implement internet censorship
No US move to rejoin Iran nuclear deal imminent, say Biden national security nominees
COVID-19 and Trump’s indifference helped human rights abusers in 2020
Central Asia vaccination plans underwhelm, but governments look unruffled
Fears of authoritarianism as Kyrgyz populist wins landslide and backing for ‘Khanstitution’
COMMENT: Mongolia is an island of democracy
OUTLOOK 2021 Mongolia
Mongolia's PM quits amid protests over treatment of mother with coronavirus and newborn baby
Mongolia's winter dzud set to be one of most extreme on record says Red Cross
Tajikistan: Writing for the president is on the wall (and then scrubbed off)
OUTLOOK 2021 Turkmenistan
Turkmenistan: How the Grinch stole New Year
COMMENT: Uzbekistan is being transformed, but where are the democratic reforms?
Download the pdf version
Russia will begin the process of certifying its Sputnik V vaccine for use in Europe on January 19, according to Kirill Dmitriev, director of the Russian Direct Investment Fund (RDIF) that funded the development of the medicine, reports Kommersant.
While the launch of Russia’s vaccine has been met with a great deal of scepticism as it was rushed through the domestic certification process in August last year and questions have been raised over the veracity of the trials data, the bottom line is no serious problems have come to light during the large-scale phase III trials so far.
And production is in full swing. Russia’s December industrial production results got a boost from the heavy investment and activity from the pharmaceutical sector – not a traditional Russian economic driver – thanks to the scaling up of Sputnik V’s production.
The Kremlin launched a mass inoculation roll out in December – the first country in the world to do so – offering the vaccine to all Russian citizens for free. It claims to have already inoculated 1.5mn people, although here too the Kremlin has been accused of inflating the numbers.
On the flip side Germany, where much of the scientific research was done to identify the virus, produce an effective test for it and develop of one of the working vaccines, has found itself short of supplies, thanks to a procurement screw-up: Germany had counted on several candidate vaccines being certified, whereas fewer actually were, so it didn't order enough doses from the available pool. The upshot is that despite being in the vanguard of the scientific effort to fight the virus, Germany will be in the baggage train in terms of actually rolling out a mass inoculation campaign.
Dmitriev claims that a scientific review of Sputnik V will begin in Germany on January 19 – the first step in certifying the vaccine for use in Germany, as the Bundestag scrambles to lay its hands on enough vaccine to inoculate its 80mn strong population, the largest in Europe after Russia’s.
An application for an emergency use authorisation (EUA) for the Sputnik V vaccine was submitted by RDIF to the German authorities on December 22.
The process of registration of the Russian vaccine with the European Medicines Agency (EMA) was also submitted at the end of October.
So far, EMA has registered only two vaccines: the joint production of Pfizer (USA) and BioNTech (Germany), as well as that from Moderna (USA). Other candidates from the UK and Asia have not yet been approved.
As time has passed, the international media have begun to warm to the Russian vaccine, which its producers, the Gamaleya Research Institute of Epidemiology and Microbiology, claim has an efficacy of over 90%.
“All over the world, except for a number of Western countries, the attitude towards the Russian vaccine is positive, and Russian medicine is recognised as one of the world leaders," Dmitriev told Kommersant. "This is confirmed by a survey conducted by YouGov in 11 largest developing countries, where one third of the world's population lives, which showed that more than 80% of respondents trust the platform on which Sputnik V is based and are well aware of the Russian vaccine." The survey was conducted in the countries of the Middle East and Southeast Asia.
Sputnik V has already generated the fourth most orders in the global coronavirus (COVID-19) vaccine market that is by some estimates worth up to $100bn. The Kremlin has also been using the vaccine as a political tool to promote its soft power relations with its allies, by offering discounted versions of the vaccine or joint production deals to its friends. Joint production of Sputnik V is due to be set up in Kazakhstan and Turkey, whereas Belarus is due to receive its first shipment in February. All-in-all Russia has done deals with some 50 countries, according to the RDIF.
Most recently, a small scandal was provoked in Ukraine where a pharmaceutical firm linked to Viktor Medvedchuk, the head of the pro-Russia Political Council of the Opposition Platform, the For Life Party, and a personal friend of Russian President Vladimir Putin, applied for a joint production licence for Sputnik V. Ukrainian President Volodymyr Zelenskiy has also hinted that Kyiv might be open to buying the vaccine from Russia, as his country is struggling to source dose from the West.
“In some Western countries there was initially a prejudice against our vaccine caused by unfair competition, but even in these countries they now understand the advantages of Sputnik V, such as more than 90% efficacy, a proven and safe platform for the human adenovirus vector, the absence of severe allergic reactions and ease of storage (at a temperature of two to eight degrees)," Dmitriev added. According to him, Sputnik V is already registered in seven countries, and will add another ten in the near future.
The fact that Sputnik V can be stored at room temperature is also a big plus, as the western vaccines based on RNA messenger technology have to be stored at -70C, making them difficult and costly to transport. Overall the Sputnik V vaccine is about a third of the price of its western counterparts, adding to its appeal to Russia’s traditional partners in the Commonwealth of Independent States (CIS) and other emerging markets.
“Now the vaccine is already being produced in Korea and India,” Dmitriev said. “Production in Brazil will begin on January 15 and production in China is planned. In addition to the Russian Federation, only eight countries will produce the Russian vaccine.”
here to continue reading this article
and 5 more for free or purchase
12 months full website access including
the bne Magazine for just $250/year.
Register to read the bne monthly magazine for
Password could contain only
and have 8-20 symbols length.
Please complete your registration by confirming your
A confirmation email has been sent to the email
address you provided.
can't be empty.
No user with
this email address.
Access recovery request has expired, or you are using
the wrong recovery token. Please, try again.
Access recover request has expired.
Please, try again.
To continue viewing our content you need to complete
the registration process.
Please look for an email that was sent to
with the subject line
"Confirmation bne IntelliNews access". This email will have
instructions on how to complete registration
process. Please check in your "Junk" folder in
case this communication was misdirected in your
If you have any questions please contact us at firstname.lastname@example.org
Sorry, but you have used all your free articles fro
this month for bne IntelliNews. Subscribe
to continue reading for only $119 per year.
Your subscription includes:
For the meantime we are also offering a free
digital weekly newspaper to subscribers to
the online package.
Click here for more subscription options,
including to the print version of our
flagship monthly magazine:
Take a trial to our premium daily news
service aimed at professional investors that
covers the 30 countries of emerging
For any other enquiries about our
products or corporate discounts please
contact us at
If you no longer wish to receive
Magazine annual print
Website & Archive
Combined package: web
access & magazine print
Take a trial to our premium daily news service
aimed at professional investors that
covers the 30 countries of emerging Europe: